Be the first person to write a business review for Biolex Therapeutics, Inc.

BioMarin Pharmaceutical Inc. company was founded in 1996 and is headquartered in Novato, California. BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises approved products and multiple investigational product candidates. The company's approved products include Naglazyme (galsulfase), a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used to treat genetic disease called mucopolysaccharidosis (MPS)VI; Kuvan (sapropterin dihydrochloride), a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase indicated for patients with Phenylketonuria (PKU); and Aldurazyme (laronidase) that is used to treat mucopolysaccharidosis I caused by the deficiency of a lysosomal enzyme called alpha-L-iduronidase.Its clinical development products comprise various product candidates for the treatment of genetic diseases, which include PEG-PAL, an enzyme substitution therapy under Phase I clinical development to treat phenylketonurics, which are not responsive to Kuvan; 6R-BH4, a Phase II clinical development product for the treatment of multiple cardiovascular indications, including sickle cell disease; and GALNS, an enzyme replacement therapy for MPS Type IV or Morquio Syndrome Type A (MPS IV A), a lysosomal storage disease. In addition, the company is conducting preclinical development of various other enzyme product candidates for genetic and other diseases, including a small molecule for the treatment of Duchenne muscular dystrophy. Further, BioMarin holds rights to receive royalties related to Orapred and Orapred ODT as a result of sublicense of North American rights. The company sells its products to specialty pharmacies, hospitals acting as retailers, and pharmaceutical wholesalers in the United States, Europe, and internationally. It has a strategic alliance with Merck Serono S.A. and joint venture with Genzyme Corporation.

BioMS Medical Corp. was founded in 1998 and is headquartered in Edmonton, Canada. BioMS Medical Corp., a development stage biotechnology company, through its subsidiaries, engages in the development and commercialization of therapeutic technologies for the treatment of multiple sclerosis (MS) in Canada. Its lead product under development includes Dirucotide for the treatment of multiple sclerosis, which is being evaluated in two pivotal Phase III clinical trials for secondary progressive MS patients; and MAESTRO-01, a pivotal phase II/III trial in Canada and western Europe. The company also develops Maestro-02, an open-label follow-on study to the Maestro-01 pivotal phase II/III clinical trial of Dirucotide, which targets secondary progressive multiple sclerosis (SPMS), as well as MAESTRO-03 trial, a pivotal Phase III product to evaluate the safety and efficacy of Dirucotide in patients with SPMS in the United States. BioMS Medical Corp. has a licensing and development agreement with Eli Lilly and Company. The company was formerly known as EPS Capital Corp. and changed its name to BioMS Medical Corp. in July 2001.

Bionovo, Inc. company was founded in 2002 and is based in Emeryville, California. Bionovo, Inc. is a clinical stage drug discovery and development company focusing on women’s health and cancer. The Company designs drugs derived from botanical sources, which have mechanisms of action. The Company’s drug candidate, Menerba, represents a class of receptor sub-type selective estrogen receptor modulator (SERM) for the treatment of vasomotor symptoms of menopause, or hot flashes. The Company has designed Menerba to selectively modulate estrogen receptor beta (ERβ). In preclinical studies, Menerba inhibited tumor growth, as well as bone resorption known to cause osteoporosis, which is developed during menopause. The Company was developing BZL101, an oral anti-cancer agent for advanced breast cancer during the year ended December 31, 2008. BZL101 is designed to take advantage of the metabolism of cancer cells. BZL101 inhibits glycolysis, a metabolic pathway on which cancer cells rely.

England's Northwest region is a hotbed of biotechnology growth. It's Bionow's job to make the region even hotter -- and turn it into the center of biomanufacturing in Europe. Funded by the Northwest Development Agency, Bionow promotes and encourages growth in the area, which is already home to a plethora of biomanufacturing facilities for companies such as AstraZeneca, Eli Lilly, and Chiron Vaccines. Bionow offers information on companies, facilities, and services in the region, promotes educational and networking events, and organizes overseas trade missions. The Northwest also has several academic research centers in Liverpool and Manchester.

BioNumerik Pharmaceuticals does biopharmaceutical drug development by the numbers. Using a multi-discipline process of identifying potential cancer drugs, the company has brought two candidates into late-stage development. Lead candidate Tavocept, which has FDA fast-track status, may prevent nerve and kidney damage caused by cancer therapies. BioNumerik's Karenitecin candidate is an advanced formulation of an existing cancer drug and is being evaluated for treatment of solid tumors. The firm relies heavily on computer models and simulations to identify promising drug candidates. In addition to its two lead candidates, it has several other potential drugs in pre-clinical research.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.